The B2M is the subunit necessary for antigen presentation by MHC-1 and the tumor resistant anti-CTLA-4 or anti-PD-1 therapy no longer express B2M (Sade-Feldman et al., 2017). This evidence concerns the gene B2M and neoplasm.